Protein Kinase C β/Early Growth Response-1 Pathway. A Key Player in Ischemia, Atherosclerosis, and Restenosis

Journal of the American College of Cardiology

Volumn 48, Issue 9 SUPPL., 2006, Pages

  Yan, Shi Fang ^a   Harja, Evis ^a   Andrassy, Martin ^a   Fujita, Tomoyuki ^a   Schmidt, Ann Marie ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; EARLY GROWTH RESPONSE FACTOR 1; FIBRINOGEN RECEPTOR ANTAGONIST; LY 379196; PACLITAXEL; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN KINASE C BETA; RAPAMYCIN; RUBOXISTAURIN;

ATHEROSCLEROSIS; BINDING AFFINITY; CELL DIFFERENTIATION; CLINICAL TRIAL; DRUG ELUTING STENT; ENZYME ACTIVATION; FIBRIN DEPOSITION; GENETIC TRANSCRIPTION; GLOMERULUS FILTRATION; HEART MUSCLE ISCHEMIA; HOMEOSTASIS; HUMAN; IMMUNOHISTOCHEMISTRY; LABORATORY; MORBIDITY; MORTALITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REPERFUSION INJURY; RESTENOSIS; REVIEW; SIGNAL TRANSDUCTION; UPREGULATION; VASCULAR DISEASE;

ANIMALS; CORONARY ARTERIOSCLEROSIS; CORONARY RESTENOSIS; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; DISEASE MODELS, ANIMAL; EARLY GROWTH RESPONSE PROTEIN 1; ENDOTHELIUM, VASCULAR; HUMANS; INDOLES; MALEIMIDES; MICE; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MYOCARDIAL ISCHEMIA; OXIDATIVE STRESS; PHOSPHORYLATION; PROTEIN KINASE C; SIGNAL TRANSDUCTION; TUNICA INTIMA; UP-REGULATION;

EID: 33750433553     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2006.05.063     Document Type: Review

References (109)

1. Chien K.R. Genes and physiology: molecular physiology in genetically engineered animals. J Clin Invest 97 (1996) 901-909
2. Milbrandt J. A nerve growth factor induced gene encodes a possible transcriptional regulatory factor. Science 238 (1987) 797-799
3. Gashler A., and Sukhatme V. Egr-1: prototype of a zinc finger family of transcription factors. Prog Nucleic Acid Res Mol Biol 50 (1995) 191-224
4. Nguyen H., Hoffman-Liebermann B., and Liebermann D. Egr-1 is essential for and restricts differentiation along the macrophage cell lineage. Cell 72 (1993) 197-209
5. Lee S.L., Sadovsky Y., Swirnoff A.H., Polish J.A., Goda P., Gavrilina G., and Milbrandt J. Luteinizing hormone deficiency and female infertility in mice lacking the transcription factor NGF1-A (Egr-1). Science 273 (1996) 1219-1221
6. Dorn C., Ou Q., Svaren J., Crawford P.A., and Sadovsky Y. Activation of luteinizing hormone β gene by gonadotropin-releasing hormone requires the synergy of early growth response-1 and steroidogenic factor-1. J Biol Chem 274 (1999) 13870-13876
7. Khachigian L., and Collins T. Inducible expression of Egr-1 dependent genes. A paradigm of transcriptional activation in vascular endothelium. Circ Res 81 (1997) 457-461
8. Khachigian L., Williams A., and Collins T. Interplay of Sp1 and Egr-1 in the proximal PDGF A-chain promoter in cultured vascular endothelial cells. J Biol Chem 270 (1995) 27679-27686
9. Silverman E.S., and Collin T. Pathways of Egr-1 mediated gene transcription in vascular biology. Am J Pathol 154 (1999) 665-670
10. Yan S.F., Zou Y.S., Gao Y., et al. Tissue factor transcription driven by Egr-1 is a critical mechanism of murine pulmonary fibrin deposition in hypoxia. Proc Natl Acad Sci U S A 95 (1998) 8298-8303
11. Yan S.F., Lu J., Zou Y.S., et al. Hypoxia-associated induction of early growth response-1 gene expression. J Biol Chem 274 (1999) 15030-15040
12. Yan S.F., Lu J., Zou Y.S., et al. Protein kinase C-β and oxygen deprivation. A novel Egr-1-dependent pathway for fibrin deposition in hypoxemic vasculature. J Biol Chem 275 (2000) 11921-11928
13. Yan S.F., Fujita T., Lu J., et al. Egr-1, a master switch coordinating upregulation of divergent gene families underlying ischemic stress. Nat Med 6 (2000) 1355-1361
14. Fujita T., Asai T., Andrassy M., et al. PKCβ regulates ischemia/reperfusion injury in the lung. J Clin Invest 113 (2004) 1615-1623
15. Akai Y., Homma T., Burns K.D., Yasuda T., Badr K.F., and Harris R.C. Mechanical stretch/relaxation of cultured rat mesangial cells induces protooncogenes and cyclooxygenase. Am J Physiol 267 (1994) C482-C490
16. Houston P., Dickson M.C., Ludbrook V., et al. Fluid shear stress induction of the tissue factor promoter in vitro and in vivo is mediated by Egr-1. Arterioscler Thromb Vasc Biol 19 (1999) 281-289
17. Houston P., White B.P., Campbell C.J., and Braddock M. Delivery and expression of fluid shear stress-inducible promoters to the vessel wall: applications for cardiovascular gene therapy. Hum Gene Ther 10 (1999) 3031-3044
18. Zhang W., Yan S.D., Zhu A., et al. Expression of Egr-1 in late stage emphysema. Am J Pathol 157 (2000) 1311-1320
19. McCaffrey T.A., Fu C., Du B., et al. High level expression of Egr-1 and Egr-1 inducible genes in mouse and human atherosclerosis. J Clin Invest 105 (2000) 653-662
20. Topol E.J., and Serruys P.W. Frontiers in interventional cardiology. Circulation 98 (1998) 1802-1820
21. Harja E., Bucciarelli L.G., Lu Y., et al. Early growth response-1 promotes atherogenosis: mice deficient in early growth response-1 and apolipoprotein E display decreased atherosclerosis and vascular inflammation. Circ Res 94 (2004) 333-339
22. Khachigian L.M., Lindner V., Williams A.J., and Collins T. Egr-1-induced endothelial gene expression: a common theme in vascular injury. Science 271 (1996) 1427-1431
23. Santiago F., Lowe H., Day F., Chesterman C., and Khachigian L. Egr-1 induction by injury is triggered by release and paracrine activation by FGF-2. Am J Pathol 154 (1999) 937-944
24. Santiago F., Lowe H.C., Kavurma M.M., et al. New DNA enzyme targeting Egr-1 mRNA inhibits vascular smooth muscle proliferation and regrowth after injury. Nat Med 5 (1999) 1264-1269
25. Andrassy M., Belov D., Harja E., et al. Central role of PKCβ in neointimal expansion triggered by acute arterial injury. Circ Res 96 (2005) 476-483
26. Idris I., Gray S., and Donnelly R. Protein kinase C activation: isozyme-specific effects on metabolism and cardiovascular complications in diabetes. Diabetologia 44 (2001) 659-673
27. Newton A.C. Protein kinase C: structure, function, and regulation. J Biol Chem 270 (1995) 28495-28498
28. Nishizuka Y. The role of protein kinase C in cell surface signal transduction and tumour promotion. Nature 308 (1984) 693-698
29. Ceolotto G., Gallo A., Miola M., et al. Protein kinase C activity is acutely regulated by plasma glucose concentration in human monocytes in vivo. Diabetes 48 (1999) 1316-1322
30. Scivittaro V., Ganz M.B., and Weiss M.F. AGEs induce oxidant stress and activate protein kinase PKCβII in neonatal mesangial cells. Am J Physiol Renal Physiol 278 (2000) F676-F683
31. Braiman L., Sheffi-Friedman L., Bak A., Tennenbaum T., and Sampson S. Tyrosine phosphorylation of specific protein kinase C isoenzymes participates in insulin stimulation of glucose transport in primary cultures of rat skeletal muscle. Diabetes 48 (1999) 1922-1929
32. Bandyopadhyay G., Standaert M., Galloway L., Moscat J., and Farese R. Evidence for involvement of protein kinase C zeta and noninvolvement of diacylglycerol sensitive PKCs in insulin-stimulated glucose transport in L6 myotubes. Endocrinology 138 (1997) 4721-4731
33. Park J.Y., Takahara N., and Gabriele A. Induction of endothelin-1 expression by glucose: an effect of PKC activation. Diabetes 49 (2000) 1239-1248
34. Takagi C., Bursell S.E., Lin Y.W., et al. Regulation of retinal hemodynamics in diabetic rats by increased expression and action of ET-1. Invest Ophthalmol Vis Sci 37 (1996) 2504-2518
35. Sharma K., Danoff T., DePierro A., and Ziyadeh F.N. Enhanced expression of inducible nitric oxide synthase in murine macrophages and glomerular mesangial cells by elevated glucose levels: possible mediation by PKC. Biochem Biophys Res Commun 207 (1995) 80-88
36. Kreuzer J., Denger S., Schmidts A., Jahn L., Merten M., and von Hodenberg E. Fibrinogen promotes monocyte adhesion via a PKC dependent mechanism. J Mol Med 74 (1996) 161-165
37. Kalra V.K., Shen Y., Sultana C., and Rattan V. Hypoxia induces PECAM-1 phosphorylation and transendothelial migration of monocytes. Am J Physiol 271 (1996) H2025-H2034
38. Park C.W., Kim J.H., Lee J.W., et al. High glucose induced intercellular adhesion molecule-1 expression through an osmotic effect in rat mesangial cells is PKC-NF-kB-dependent. Diabetologia 43 (2000) 1544-1553
39. Harja E., Lu Y., Zou Y.S., et al. Central roles for PKCβ/early growth response-1 (Egr-1) axis in atherosclerosis in apolipoprotein E null mice. Circulation 108 (2003) 1429
40. Harja E., Hudson B.I., Zou Y.S., Lu Y., Schmidt A.M., and Yan S.F. PKC beta/Egr-1: a central axis in atherosclerosis. FASEB J 19 (2005) 387.20
41. Leitges M., Schmedt C., Guinamard R., et al. Immunodeficiency in protein kinase Cβ deficient mice. Science 273 (1996) 788-791
42. Nechushtan H., Leitges M., Cohen C., Kay G., and Razin E. Inhibition of degranulation and IL-6 production in mast cells derived from mice deficient in PKCβ. Blood 95 (2000) 1752-1757
43. Standaert M.L., Bandyopadhyay G., Galloway L., et al. Effects of knockout of the PKCβ gene on glucose transport and glucose homeostasis. Endocrinology 140 (1999) 440-447
44. Yan S.F., Zou Y.S., Mendelsohn M., et al. Nuclear factor interleukin 6 motifs mediate tissue-specific gene transcription in hypoxia. J Biol Chem 14 (1997) 4287-4294
45. Okada K., Fujita T., Minamoto K., Liao H., Naka Y., and Pinsky D.J. Potentiation of endogenous fibrinolysis and rescue from lung ischemia-reperfusion injury in IL-10-reconstituted IL-10 null mice. J Biol Chem 275 (2000) 21468-21475
46. Semenza G.L. Surviving ischemia: adaptive responses mediated by hypoxia-inducible factor 1. J Clin Invest 106 (2000) 809-812
47. Semenza G. Perspectives on oxygen sensing. Cell 98 (1999) 281-284
48. Zhu H., and Bunn H. Oxygen sensing and signaling impact on the regulation of physiologically important genes. Respir Physiol 115 (1999) 239-247
49. Ratcliffe P.J., O'Rourke J.F., Maxwell P.H., and Pugh C.W. Oxygen sensing, hypoxia-inducible factor-1 and the regulation of mammalian gene expression. J Exp Biol 201 (1998) 1153-1162
50. Karakurum M., Shreeniwas R., Chen J., et al. Hypoxic induction of interleukin-8 gene expression in human endothelial cells. J Clin Invest 93 (1994) 1564-1570
51. Royds J.A., Dower S.K., Qwarnstrom E.E., and Lewis C.E. Response of tumour cells to hypoxia: role of p53 and NFkB. Mol Pathol 51 (1998) 55-61
52. Schmedtje Jr. J.F., Ji Y.S., Liu W.L., DuBois R.N., and Runge M.S. Hypoxia induces cyclooxygenase-2 via the NF-kappaB p65 transcription factor in human vascular endothelial cells. J Biol Chem 272 (1997) 601-608
53. Cui M.Z., Parry G.C., Oeth P., et al. Transcriptional regulation of the tissue factor gene in human epithelial cells is mediated by Sp1 and EGR-1. J Biol Chem 2 (1996) 2731-2739
54. Groupp E.R., and Donovan-Peluso M. Lipopolysaccharide induction of THP-1 cells activates binding of c-Jun, Ets, and Egr-1 to the tissue factor promoter. J Biol Chem 24 (1996) 12423-12430
55. Troller U., Zeidman R., Svensson K., and Larsson C. A PKCβ isoform mediates phorbol ester-induced activation of ERK1/2 and expression of neuronal differentiation genes in neuroblastoma cells. FEBS Lett 508 (2001) 126-130
56. Bogoyevitch M.A., Gillespie-Brown J., Ketterman A.J., et al. Stimulation of the stress-activated mitogen-activated protein kinase subfamilies in perfused heart. P38/RK mitogen-activated protein kinases and c-Jun N-terminal kinases are activated by ischemia/reperfusion. Circ Res 79 (1996) 162-173
57. Knight R.J., and Buxton D.B. Stimulation of c-Jun kinase and mitogen-activated protein kinase by ischemia and reperfusion in the reperfused rat heart. Biochem Biophys Res Commun 218 (1996) 83-88
58. Yin T., Sandhu G., Wolfgang C.D., et al. Tissue-specific pattern of stress kinase activation in ischemic/reperfused heart and kidney. J Biol Chem 272 (1997) 19943-19950
59. Clerk A., Fuller S.J., Michael A., and Sugden P.H. Stimulation of "stress-regulated" mitogen-activated protein kinases (stress-activated protein kinases/c-Jun N-terminal kinases and p38-mitogen-activated protein kinases) in perfused rat hearts by oxidative and other stresses. J Biol Chem 273 (1997) 7228-7234
60. Laderoute K.R., and Webster K.A. Hypoxia/reoxygenation stimulates Jun kinase activity through redox signaling in cardiac myocytes. Circ Res 80 (1997) 336-344
61. Hreniuk D., Garay M., Gaarde W., Monia B.P., McKay R.A., and Cioffi C.L. Inhibition of c-Jun N-terminal kinase 1, but not c-Jun N-terminal kinase 2, suppresses apoptosis induced by ischemia/reoxygenation in rat cardiac myocytes. Mol Pharmacol 59 (2001) 867-874
62. Yue T.L., Ma X.L., Wang X., et al. Possible involvement of stress-activated protein kinase signaling pathway and Fas receptor expression in prevention of ischemia/reperfusion-induced cardiomyocyte apoptosis by carvedilol. Circ Res 82 (1998) 166-167
63. Pombo C.M., Bonventre J.V., Avruch J., Woodgett J.R., Kyriakis J.M., and Force T. The stress-activated protein kinases are major c-Jun amino terminal kinases activated by ischemia and reperfusion. J Biol Chem 269 (1994) 26546-26551
64. Ozawa H., Shioda S., Dohi K., et al. Delayed neuronal cell death in the rat hippocampus is mediated by the mitogen-activated protein kinase signal transduction pathway. Neurosci Lett 262 (1999) 57-60
65. Pang L., Sawada T., Decker S.J., and Saltiel A.R. Inhibition of MAP kinase blocks the differentiation of PC-12 cells induced by nerve growth factor. J Biol Chem 270 (1995) 13585-13588
66. Bennett B.L., Sasaki D.T., Murray B.W., et al. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci U S A 98 (2001) 13681-13686
67. Cuenda A., Rouse J., Doza Y.N., et al. SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1. FEBS Lett 364 (1995) 229-233
68. Danis R.P., Bingaman D.P., Jirousek M., and Yang Y. Inhibition of intraocular neovascularization caused by retinal ischemia in pigs by PKCβ inhibition with LY333531. Invest Ophthalmol Vis Sci 39 (1998) 171-179
69. Ishii H., Jirousek M.R., Koya D., et al. Amelioration of vascular dysfunction in diabetic rats by an oral PKCβ inhibitor. Science 272 (1996) 728-731
70. Bursell S.E., Takagi C., Clermont A.C., et al. Specific retinal DAG and PKCβ isoform modulation mimics abnormal retinal hemodynamics in diabetic rats. Invest Ophthalmol Vis Sci 38 (1997) 2711-2720
71. Aiello L.P., Bursell S.E., Clermont A., et al. Vascular endothelial growth factor induced retinal permeability is mediated by PKC in vivo and suppressed by an orally effective β-isoform selective inhibitor. Diabetes 46 (1997) 1473-1480
72. Andrassy M., Szabolcs M.J., Yan S.D., et al. PKCβ modulates ischemia reperfusion injury in the heart. AHA Scientific Sessions 2004. Circulation 110 (2004) 517
73. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 340 (1999) 115-126
74. Glass C.K., and Witztum J.L. Atherosclerosis: the road ahead. Cell 104 (2001) 503-516
75. Libby P. Inflammation in atherosclerosis. Nature 420 (2002) 868-874
76. Ross R., Glomset J., and Harker L. Response to injury and atherogenesis. Am J Pathol 86 (1977) 675-684
77. Bavendiek U., Libby P., Kilbride M., Reynolds R., Mackman N., and Schonbeck U. Induction of tissue factor expression in human endothelial cells via CD40 ligand is mediated by AP-1, NF-kB, and Egr-1. J Biol Chem 277 (2002) 25032-25039
78. Fu M., Zhang J., Lin Y., Ehrengruber M.U., and Chen Y.E. Early growth response factor-1: a critical transcriptional mediator of peroxisome proliferator activated receptor gamma 1 gene expression in human aortic smooth muscle cells. J Biol Chem 277 (2002) 26808-26814
79. Du B., Fu C., Kent K.C., et al. Elevated Egr-1 in human atherosclerotic cells transcriptionally represses the transforming growth factor-beta type II receptor. J Biol Chem 275 (2000) 39039-39047
80. Kadl A., Huber J., Gruber F., Bochkov V.N., Binder B.R., and Leitinger N. Analysis of inflammatory gene induction by oxidized phospholipids in vivo by quantitative real-time RT-PCR in comparison with effects of LPS. Vasc Pharmacol 38 (2002) 219-227
81. Rupp J., and Maass M. Egr-1, a major link between infection and atherosclerosis?. Circ Res 92 (2003) 78
82. Bea F., Puolakkainen M.H., McMillen T., et al. Chlamydia pneumoniae induces tissue factor expression in mouse macrophages via activation of Egr-1 and the MEK-ERK1/2 pathway. Circ Res 92 (2003) 394-401
83. Holmes Jr. D.R., Viestra R.E., Smith H.C., et al. Restenosis after percutaneous translational angioplasty (PTCA): a report from the PTCA Registry of the National Heart, Lung, and Blood Institute. Am J Cardiol 53 (1984) 77C-81C
84. Serruys P.W., Luijten H.E., Beatt K.J., et al. Incidence of restenosis after successful coronary angioplasty: a time-related phenomenon: a quantitative angiographic study in 342 consecutive patients at 1, 2, 3, and 4 months. Circulation 77 (1988) 361-371
85. Weintraub W.S., Kosinski A.S., Brown C.L., and King S.B. Can restenosis after coronary angioplasty be predicted from clinical variables?. J Am Coll Cardiol 21 (1993) 6-14
86. Vandormael M.G., Deligonul U., Kern M.U., et al. Multilesion coronary angioplasty: clinical and angiographic outcome. J Am Coll Cardiol 10 (1987) 246-252
87. Quigley P.J., Hlatky M.A., Hinohara T., et al. Repeat percutaneous transluminal coronary angioplasty and predictors of recurrent restenosis. Am J Cardiol 63 (1989) 409-413
88. Rensing B.J., Hermans W.R., Vos J., et al. Luminal narrowing after percutaneous transluminal coronary angioplasty. Circulation 88 (1993) 975-985
89. Serruys P.W., de Jaegere P., Kiemeneij F., et al., Benestent Study Group. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med 331 (1994) 489-495
90. Fischman D.L., Leon M.B., Baim D.S., et al., Stent Restenosis Study Investigators. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med 331 (1994) 496-501
91. Aronow W.S. Management of peripheral arterial disease. Cardiol Rev 13 (2005) 61-68
92. Weitz J.I., Byrne J., Clagett G.P., et al. Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: a critical review. Circulation 94 (1996) 3026-3049
93. Palmaz J.C., Garcia O.J., Schatz R.A., et al. Placement of balloon-expandable intraluminal stents in iliac arteries. First 171 procedures. Radiology 174 (1990) 969-975
94. Bainbridge A.D., Muir D., and Fath-Ordoubadi F. A paclitaxel coated stent used for in-stent restenosis within a sirolimus coated stent fails to protect against recurrent restenosis. Heart 91 (2005) 730
95. Moussa I., Leon M.B., Baim D.S., et al. Impact of sirolimus-eluting stents on outcome in diabetic patients: a SIRIUS (SIRolImUS-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy. Circulation 109 (2004) 2273-2278
96. Goodman S. Enoxaparin and glycoprotein IIb/IIIa inhibition in non-ST-elevation acute coronary syndrome: insights from the INTERACT trial. Am Heart J 149 Suppl 4 (2005) S73-S80
97. Straub A., Azevedo R., Beierlein W., Wendel H.P., Dietz K., and Ziemer G. Glycoprotein IIb/IIIa inhibition reduces prothrombotic events under conditions of deep hypothermic circulatory arrest. Thromb Haemost 94 (2005) 115-122
98. Lowe H.C., Fahmy R.G., Kavurma M.M., Baker A., Chesterman C.N., and Khachigian L.M. Catalytic oligodeoxynucleotides define a key regulatory role for early growth response-factor 1 in the porcine model of coronary in stent restenosis. Circ Res 89 (2001) 670-677
99. Steele P.M., Chesebro J.H., Stanson A.W., et al. Balloon angioplasty: natural history of the pathophysiological response to injury in a pig model. Circ Res 57 (1985) 105-112
100. Schwartz R.S., Murphy J.G., Edwards W.D., Camrud A.R., Vlietstra R.E., and Holmes D.R. Restenosis after balloon angioplasty: a practical proliferative model in porcine coronary arteries. Circulation 82 (1990) 2190-2200
101. Roque M., Fallon J.T., Badimon J.J., Zhang W.X., Taubman M.B., and Reis E.D. Mouse model of femoral artery denudation injury associated with the rapid accumulation of adhesion molecules on the luminal surface and recruitment of neutrophils. Arterioscler Thromb Vasc Biol 20 (2000) 335-342
102. Koyama H., Olson N., Dastva F., and Reidy M. Cell replication in the arterial wall. Circ Res 82 (1998) 713-721
103. Seki Y., Shibata R., Nagata T., Yasukawa H., Yoshimura A., and Imaizumi T. Role of JAK/STAT pathway in rat carotid artery remodeling after vascular injury. Circ Res 87 (2000) 12-18
104. Jirousek M.R., Gillig J.R., Gonzalez C.M., et al. (S)-13[(dimethylamino0methyl]-10,11,14,15-tetrahydro-4,9: 16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h] [1,4,13]-oxadiazactclohexadecene-1,3(2H)-dione(ruboxistaurin) and related analogues: isozyme selective inhibitors of protein kinase Cβ. J Med Chem 39 (1996) 2664-2671
105. Tuttle K.R., and Anderson P.W. A novel potential therapy for diabetic nephropathy and vascular complications: protein kinase C beta inhibition. (review). Am J Kidney Dis 42 (2003) 456-465
106. Aiello L.P., Bursell S.E., Devries T., Alatorre C., King G.L., and Ways D.K. Amelioration of abnormal retinal hemodynamics by a protein kinase Cβ selective inhibitor (LY333531) in patients with diabetes: results of a phase 1 safety and phamacodynamic clinical trial (abstr). Invest Ophthalmol Vis Sci 40 Suppl (1999) S192
107. Aiello L.P., Clermont A., Arora V., Davis M.D., Sheetz M.J., and Bursell S.E. Inhibition of PKC beta by oral administration of ruboxistaurin is well tolerated and ameliorates diabetes-induced retinal hemodynamic abnormalities in patients. Invest Ophthalmol Vis Sci 47 (2006) 86-92
108. Kannel W.B., and MCGee D.L. Diabetes and cardiovascular disease. JAMA 241 (1979) 2035-2038
109. Beckman J.A., Goldfine A.B., Gordon M.B., Garrett L.A., and Creager M.A. Inhibition of protein kinase C prevents impaired endothelium-dependent vasodilation caused by hyperglycemia in humans. Circ Res 90 (2002) 107-111